Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1058715

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Air Pollution: Health Hazards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 February 2019 to Question 213200 on Air Pollution and with reference to p165 of the World Health Organisation report, Review of evidence on health aspects of air pollution – REVIHAAP Project, if his Department will conduct research into PM1 and PM0.1.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	219268
answer	answer is ministerial correction date of answer 19/02/2019 answer text <p>Recent assessments have been undertaken of the health effects of long-term exposure to the air pollution mixture in the United Kingdom, but no separate assessments of the impact of PM1 and PM0.1 components (particulate matter with an aerodynamic diameter smaller than 1 or 0.1 microns respectively) of particulate air pollution have been produced.</p><p> </p><p>Public Health England (PHE) undertakes various air quality research projects, working with academic partners, to review the evidence of the health effects of air pollutants. In particular, regarding the health effects of PM0.1 and PM1, PHE has a research program that looks at various aspects of the health effects of PM0.1 (nanoparticles) through the inhalational route mainly focussed on manufactured materials. However, PHE has no plans to engage in work on the effects of PM1 particles on human health over the coming year.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 219269 question first answered 19/02/2019 17:29:50 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1058716

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Air Pollution: Health Hazards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 February 2019 to Question 213200 and with reference to page six of the January 2013 report of the Health Effects Institute entitled Understanding the Health Effects of Ambient Ultrafine Particles, if he will implement the recommendations of that report on PM0.1 and PM1.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	219269
answer	answer is ministerial correction date of answer 19/02/2019 answer text <p>Recent assessments have been undertaken of the health effects of long-term exposure to the air pollution mixture in the United Kingdom, but no separate assessments of the impact of PM1 and PM0.1 components (particulate matter with an aerodynamic diameter smaller than 1 or 0.1 microns respectively) of particulate air pollution have been produced.</p><p> </p><p>Public Health England (PHE) undertakes various air quality research projects, working with academic partners, to review the evidence of the health effects of air pollutants. In particular, regarding the health effects of PM0.1 and PM1, PHE has a research program that looks at various aspects of the health effects of PM0.1 (nanoparticles) through the inhalational route mainly focussed on manufactured materials. However, PHE has no plans to engage in work on the effects of PM1 particles on human health over the coming year.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 219268 question first answered 19/02/2019 17:29:50 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1058750

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	UK Antimicrobial Resistance Diagnostics Collaborative
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what (a) representations his Department has received on the work of the UK Antimicrobial Resistance (AMR) Diagnostics Collaborative and (b) discussions have taken place between his Department and members of that group; what the timetable is for the publication of the AMR Diagnostics Collaborative's report; and (c) if he will make a statement.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	219373
answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>Over the last five years, implementation of the United Kingdom antimicrobial resistance (AMR) strategy has been overseen and driven by a cross-Government High Level Steering Group, chaired by the Chief Medical Officer for England.</p><p> </p><p>Professor Dame Sue Hill, Chief Scientific Officer for NHS England, leads work to deliver the Government’s ambitions for diagnostics as part of the strategy. NHS England established the UK AMR Diagnostics Collaborative to support delivery of the United Kingdom’s diagnostics ambitions for AMR. The Collaborative has played a valuable role in developing the diagnostics elements of the new UK five-year national action plan on AMR, published in January this year.</p><p> </p><p>The Department continues to work closely with the UK AMR Diagnostics Collaborative, which currently has no plans to publish a report.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/02/2019 17:44:29 answering member 4067 label Biography information for Steve Brine
tabling member	1604 label Biography information for Mr Virendra Sharma

1058752

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Death
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the implications for his Department's policies of the findings of the National Aids Trust report, Drug-Related Deaths in England, published by the National Aids Trust, published on 5 February 2019; and if he will make a statement.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	219400
answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>No formal assessment has been made of the National AIDS Trust report however officials will consider its findings in the development of future drugs policy. The Government is concerned by the number of drug-related deaths and is supporting local areas to develop a more joined up approach to commissioning and delivering the range of services that are essential to supporting recovery and preventing drug-related deaths.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/02/2019 17:45:27 answering member 4067 label Biography information for Steve Brine
tabling member	3973 label Biography information for Grahame Morris

1058753

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the proposed amendments to the Human Medicines Regulation 2012, what treatment areas will be excluded from the serious shortage protocol for reasons of patient safety; and if he will publish a list of medicines and formulations that will be excluded as a result.
tabling member constituency	Sunderland Central
tabling member printed	Julie Elliott
uin	219427
answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage and mitigate medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>As the explanatory memorandum of the amending Statutory Instrument acknowledges, protocols for therapeutic or generic equivalents will not be suitable for all medicines and patients. For example, such protocols would not be suitable for medicines that need to be prescribed by brand for clinical reasons, such as biological medicines. In these cases, patients would always be referred to the prescriber for any decision about their treatment before any therapeutic or generic alternative is supplied.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/02/2019 17:35:25 answering member 4067 label Biography information for Steve Brine
tabling member	4127 label Biography information for Julie Elliott

1058754

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Human Medicines (Amendment) Regulation 2019, what the system will be by which clinicians will be able to indicate whether or not an alternative (a) quantity, (b) strength, and (c) pharmaceutical form of medicine can be dispensed in line with the protocol; and how this system will be applied to regular repeat prescriptions.
tabling member constituency	Sunderland Central
tabling member printed	Julie Elliott
uin	219428
answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>A Serious Shortage Protocol is an additional tool to manage and mitigate medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective. It can only be issued by Ministers and would only be introduced in the case of a serious shortage, if it would help manage the supply situation and if clinicians think it is appropriate, after discussion with the manufacturer and/or marketing authorisation holder.</p><p> </p><p>Any protocol would need to set out what alternative quantity, pharmaceutical form, strength, therapeutic equivalent or generic equivalent can be supplied. Supply in accordance with a protocol can only be made if the protocol is in date when a prescription is presented for dispensing, whether that prescription is an acute or a repeat prescription. If appropriate, the protocol could stipulate that it does not apply to a certain type of prescription.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/02/2019 17:47:44 answering member 4067 label Biography information for Steve Brine
tabling member	4127 label Biography information for Julie Elliott

1058775

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 February 2019 to Question 215178, if he will list the (a) 17 cancers where no staging data is available and (b) 67 cancers where some of the specific tumour morphologies are unstageable.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	219404
answer	answer is ministerial correction date of answer 19/02/2019 answer text <p>For cancers diagnosed up to, and including 2017, the Tumour, Node, Metastasis (TNM7) classification of Malignant Tumours - 7th edition staging system is used. There are 17 cancer sites which have no staging rules in TNM7. These are listed in the following table.</p><p> </p><table><tbody><tr><td><p>ICD Code</p></td><td><p>Site</p></td></tr><tr><td><p>C14</p></td><td><p>Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx</p></td></tr><tr><td><p>C33</p></td><td><p>Malignant neoplasm of trachea</p></td></tr><tr><td><p>C37</p></td><td><p>Malignant neoplasm of thymus</p></td></tr><tr><td><p>C39</p></td><td><p>Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs</p></td></tr><tr><td><p>C46</p></td><td><p>Kaposi's sarcoma</p></td></tr><tr><td><p>C70</p></td><td><p>Malignant neoplasm of meninges</p></td></tr><tr><td><p>C71</p></td><td><p>Malignant neoplasm of brain</p></td></tr><tr><td><p>C75</p></td><td><p>Malignant neoplasm of other endocrine glands and related structures</p></td></tr><tr><td><p>C77</p></td><td><p>Secondary and unspecified malignant neoplasm of lymph nodes</p></td></tr><tr><td><p>C78</p></td><td><p>Secondary malignant neoplasm of respiratory and digestive organs.</p></td></tr><tr><td><p>C79</p></td><td><p>Secondary malignant neoplasm of other and unspecified sites</p></td></tr><tr><td><p>C80</p></td><td><p>Malignant neoplasm without specification of site</p></td></tr><tr><td><p>C88</p></td><td><p>Malignant immunoproliferative diseases and certain other B-cell lymphomas</p></td></tr><tr><td><p>C92</p></td><td><p>Myeloid Leukaemia</p></td></tr><tr><td><p>C93</p></td><td><p>Monocytic Leukaemia</p></td></tr><tr><td><p>C95</p></td><td><p>Leukaemia of unspecified cell type</p></td></tr><tr><td><p>C96</p></td><td><p>Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue</p></td></tr></tbody></table><p> </p><p>This can be viewed on the Union for International Cancer Control (UICC) website at the following link:</p><p> </p><p><a href="https://www.uicc.org/sites/main/files/private/TNM_Classification_of_Malignant_Tumours_Website_15%20MAy2011.pdf" target="_blank">https://www.uicc.org/sites/main/files/private/TNM_Classification_of_Malignant_Tumours_Website_15%20MAy2011.pdf</a></p><p> </p><p>For the 67 cancers where some of the specific tumour morphologies are unstageable, data is not held in the requested format.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/02/2019 17:27:45 answering member 4067 label Biography information for Steve Brine
tabling member	4056 label Biography information for Nic Dakin

1058800

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Public Health
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of nationally commissioning more public health services through community pharmacy.
tabling member constituency	Rother Valley
tabling member printed	Sir Kevin Barron
uin	219278
answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>The Government has been clear that it wants to change the focus of the health and care system onto prevention and Ministers have also set out an ambition for local pharmacies to play a stronger role in helping people stay well in the community. The Department has committed to publishing a Green Paper on prevention that will set out how these plans will be achieved in more detail. An assessment specifically focusing on the potential merits of nationally commissioning more public health services through community pharmacy has not been undertaken.</p><p>An updated list of the 1,413 pharmacies found to be eligible for the pharmacy access scheme was published in January 2018, this is publicly available and can be found at the following link:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf</a></p><p>A small proportion of the pharmacies eligible for the scheme will not receive a payment because they do not meet the payment criteria as set out in the Drug Tariff. This means their income in 2016/17 is greater than their 2015/16 income less a 1% efficiency saving, and/or their estimated income in 2017/18 and 2018/19 is greater than their 2015/16 income less a 3% efficiency saving. The number and proportion of pharmacies on the scheme in receipt of a payment, for each year that the scheme has been running, is set out in the following table.</p><table><tbody><tr><td><p> </p></td><td><p>Total number of eligible pharmacies</p></td><td><p>Total number of pharmacies receiving zero payments</p></td><td><p>Total number of pharmacies in receipt of payment</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,402</p></td><td><p>47 (3%)</p></td><td><p>1,355 (97%)</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,415<sup><sup>[1]</sup></sup></p></td><td><p>57 (4%)</p></td><td><p>1,358 (96%)</p></td></tr></tbody></table><p><sup><sup><br>[1]</sup></sup>Two additional pharmacies have been accepted on to the scheme since the publication of the updated list. This explains the difference in the figures of 1,413 and 1,415 for 2017/18.</p><p>The fees and allowances paid under the Community Pharmacy Contractual Framework (CPCF) for the provision of essential services, including dispensing, provided by community pharmacies each year from April 2015 to March 2018 are detailed in the following table, based on data provided by NHS England. The structure of fees and allowances does not allow payments just for dispensing to be isolated. These payments do not include the medicine margin that community pharmacies earn as part of the payment for essential services, which is paid through reimbursement within the drugs’ bill.</p><p>Enhanced services are locally commissioned. As such they are funded outside of the national CPCF and the Department does not hold the information sought.</p><table><tbody><tr><td><p>Time period</p></td><td><p>Total essential services funding<sup>2</sup> /£</p></td><td><p>Total national CPCF funding (essential and advanced services) less medicines margin/ £</p></td><td><p>Funding for essential services as a proportion of total national CPCF funding (essential and advanced services) less medicines margin/ %</p></td></tr><tr><td><p>2015/16</p></td><td><p>1,881,828,149</p></td><td><p>2,000,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,769,216,586</p></td><td><p>1,887,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,668,141,583</p></td><td><p>1,792,000,000</p></td><td><p>93</p></td></tr></tbody></table><p><sup><br>2</sup>This comprises the fees and allowances paid under Part IIIA: Professional Fees (Pharmacy Contractors) and Part VIA: Payment for Essential Services (Pharmacy Contractors) of the Drug Tariff, and through the Quality Payment Scheme and Pharmacy Access Scheme. This does not include medicines margin.</p><p>Within the NHS Long Term Plan, Government has committed to expanding the number of pharmacists in Primary Care Networks. These pharmacists are well placed to work alongside the wider medical team to optimise the use of medicines, promote medicines adherence and improve the clinical and cost effectiveness of prescribed medications. Identifying and supporting patients on complex polypharmacy and those with long term conditions necessitating repeat prescriptions will form an important part of their role. Alongside this, in August 2018, NHS England, announced plans for a new pilot scheme, with investment of £1 million from the Pharmacy Integration Fund to develop system leadership within pharmacy across all settings. These pharmacy leaders will set the vision to systematically tackle medicines optimisation priorities for the local population within GP Network and Integrated Care System foot prints, further supporting medicines adherence, and in turn reducing medicines wastage.</p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 219279 219280 219281 question first answered 14/02/2019 17:46:27 answering member 4067 label Biography information for Steve Brine
tabling member	392 label Biography information for Sir Kevin Barron

1058801

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will list each pharmacy in receipt of funding from the Pharmacy Access Scheme in each year since the establishment of that scheme.
tabling member constituency	Rother Valley
tabling member printed	Sir Kevin Barron
uin	219279
answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>The Government has been clear that it wants to change the focus of the health and care system onto prevention and Ministers have also set out an ambition for local pharmacies to play a stronger role in helping people stay well in the community. The Department has committed to publishing a Green Paper on prevention that will set out how these plans will be achieved in more detail. An assessment specifically focusing on the potential merits of nationally commissioning more public health services through community pharmacy has not been undertaken.</p><p>An updated list of the 1,413 pharmacies found to be eligible for the pharmacy access scheme was published in January 2018, this is publicly available and can be found at the following link:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf</a></p><p>A small proportion of the pharmacies eligible for the scheme will not receive a payment because they do not meet the payment criteria as set out in the Drug Tariff. This means their income in 2016/17 is greater than their 2015/16 income less a 1% efficiency saving, and/or their estimated income in 2017/18 and 2018/19 is greater than their 2015/16 income less a 3% efficiency saving. The number and proportion of pharmacies on the scheme in receipt of a payment, for each year that the scheme has been running, is set out in the following table.</p><table><tbody><tr><td><p> </p></td><td><p>Total number of eligible pharmacies</p></td><td><p>Total number of pharmacies receiving zero payments</p></td><td><p>Total number of pharmacies in receipt of payment</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,402</p></td><td><p>47 (3%)</p></td><td><p>1,355 (97%)</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,415<sup><sup>[1]</sup></sup></p></td><td><p>57 (4%)</p></td><td><p>1,358 (96%)</p></td></tr></tbody></table><p><sup><sup><br>[1]</sup></sup>Two additional pharmacies have been accepted on to the scheme since the publication of the updated list. This explains the difference in the figures of 1,413 and 1,415 for 2017/18.</p><p>The fees and allowances paid under the Community Pharmacy Contractual Framework (CPCF) for the provision of essential services, including dispensing, provided by community pharmacies each year from April 2015 to March 2018 are detailed in the following table, based on data provided by NHS England. The structure of fees and allowances does not allow payments just for dispensing to be isolated. These payments do not include the medicine margin that community pharmacies earn as part of the payment for essential services, which is paid through reimbursement within the drugs’ bill.</p><p>Enhanced services are locally commissioned. As such they are funded outside of the national CPCF and the Department does not hold the information sought.</p><table><tbody><tr><td><p>Time period</p></td><td><p>Total essential services funding<sup>2</sup> /£</p></td><td><p>Total national CPCF funding (essential and advanced services) less medicines margin/ £</p></td><td><p>Funding for essential services as a proportion of total national CPCF funding (essential and advanced services) less medicines margin/ %</p></td></tr><tr><td><p>2015/16</p></td><td><p>1,881,828,149</p></td><td><p>2,000,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,769,216,586</p></td><td><p>1,887,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,668,141,583</p></td><td><p>1,792,000,000</p></td><td><p>93</p></td></tr></tbody></table><p><sup><br>2</sup>This comprises the fees and allowances paid under Part IIIA: Professional Fees (Pharmacy Contractors) and Part VIA: Payment for Essential Services (Pharmacy Contractors) of the Drug Tariff, and through the Quality Payment Scheme and Pharmacy Access Scheme. This does not include medicines margin.</p><p>Within the NHS Long Term Plan, Government has committed to expanding the number of pharmacists in Primary Care Networks. These pharmacists are well placed to work alongside the wider medical team to optimise the use of medicines, promote medicines adherence and improve the clinical and cost effectiveness of prescribed medications. Identifying and supporting patients on complex polypharmacy and those with long term conditions necessitating repeat prescriptions will form an important part of their role. Alongside this, in August 2018, NHS England, announced plans for a new pilot scheme, with investment of £1 million from the Pharmacy Integration Fund to develop system leadership within pharmacy across all settings. These pharmacy leaders will set the vision to systematically tackle medicines optimisation priorities for the local population within GP Network and Integrated Care System foot prints, further supporting medicines adherence, and in turn reducing medicines wastage.</p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 219278 219280 219281 question first answered 14/02/2019 17:46:27 answering member 4067 label Biography information for Steve Brine
tabling member	392 label Biography information for Sir Kevin Barron

1058802

registered interest
date	11/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Expenditure
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much and proportion of pharmacy funding has been spent on (a) dispensing and (b) enhanced services in each year since 2015-16.
tabling member constituency	Rother Valley
tabling member printed	Sir Kevin Barron
uin	219280
answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>The Government has been clear that it wants to change the focus of the health and care system onto prevention and Ministers have also set out an ambition for local pharmacies to play a stronger role in helping people stay well in the community. The Department has committed to publishing a Green Paper on prevention that will set out how these plans will be achieved in more detail. An assessment specifically focusing on the potential merits of nationally commissioning more public health services through community pharmacy has not been undertaken.</p><p>An updated list of the 1,413 pharmacies found to be eligible for the pharmacy access scheme was published in January 2018, this is publicly available and can be found at the following link:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/670305/PhAS_List_20122017_updated.pdf</a></p><p>A small proportion of the pharmacies eligible for the scheme will not receive a payment because they do not meet the payment criteria as set out in the Drug Tariff. This means their income in 2016/17 is greater than their 2015/16 income less a 1% efficiency saving, and/or their estimated income in 2017/18 and 2018/19 is greater than their 2015/16 income less a 3% efficiency saving. The number and proportion of pharmacies on the scheme in receipt of a payment, for each year that the scheme has been running, is set out in the following table.</p><table><tbody><tr><td><p> </p></td><td><p>Total number of eligible pharmacies</p></td><td><p>Total number of pharmacies receiving zero payments</p></td><td><p>Total number of pharmacies in receipt of payment</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,402</p></td><td><p>47 (3%)</p></td><td><p>1,355 (97%)</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,415<sup><sup>[1]</sup></sup></p></td><td><p>57 (4%)</p></td><td><p>1,358 (96%)</p></td></tr></tbody></table><p><sup><sup><br>[1]</sup></sup>Two additional pharmacies have been accepted on to the scheme since the publication of the updated list. This explains the difference in the figures of 1,413 and 1,415 for 2017/18.</p><p>The fees and allowances paid under the Community Pharmacy Contractual Framework (CPCF) for the provision of essential services, including dispensing, provided by community pharmacies each year from April 2015 to March 2018 are detailed in the following table, based on data provided by NHS England. The structure of fees and allowances does not allow payments just for dispensing to be isolated. These payments do not include the medicine margin that community pharmacies earn as part of the payment for essential services, which is paid through reimbursement within the drugs’ bill.</p><p>Enhanced services are locally commissioned. As such they are funded outside of the national CPCF and the Department does not hold the information sought.</p><table><tbody><tr><td><p>Time period</p></td><td><p>Total essential services funding<sup>2</sup> /£</p></td><td><p>Total national CPCF funding (essential and advanced services) less medicines margin/ £</p></td><td><p>Funding for essential services as a proportion of total national CPCF funding (essential and advanced services) less medicines margin/ %</p></td></tr><tr><td><p>2015/16</p></td><td><p>1,881,828,149</p></td><td><p>2,000,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,769,216,586</p></td><td><p>1,887,000,000</p></td><td><p>94</p></td></tr><tr><td><p>2017/18</p></td><td><p>1,668,141,583</p></td><td><p>1,792,000,000</p></td><td><p>93</p></td></tr></tbody></table><p><sup><br>2</sup>This comprises the fees and allowances paid under Part IIIA: Professional Fees (Pharmacy Contractors) and Part VIA: Payment for Essential Services (Pharmacy Contractors) of the Drug Tariff, and through the Quality Payment Scheme and Pharmacy Access Scheme. This does not include medicines margin.</p><p>Within the NHS Long Term Plan, Government has committed to expanding the number of pharmacists in Primary Care Networks. These pharmacists are well placed to work alongside the wider medical team to optimise the use of medicines, promote medicines adherence and improve the clinical and cost effectiveness of prescribed medications. Identifying and supporting patients on complex polypharmacy and those with long term conditions necessitating repeat prescriptions will form an important part of their role. Alongside this, in August 2018, NHS England, announced plans for a new pilot scheme, with investment of £1 million from the Pharmacy Integration Fund to develop system leadership within pharmacy across all settings. These pharmacy leaders will set the vision to systematically tackle medicines optimisation priorities for the local population within GP Network and Integrated Care System foot prints, further supporting medicines adherence, and in turn reducing medicines wastage.</p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 219278 219279 219281 question first answered 14/02/2019 17:46:27 answering member 4067 label Biography information for Steve Brine
tabling member	392 label Biography information for Sir Kevin Barron